Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pseudomonas Infections 1Pancreatic Neoplasms 1Neutropenia 1Neoplasms 1Liver Neoplasms 1Gram-Positive Bacterial Infections 1Fever 1Febrile Neutropenia 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 12Radiosurgery 5Gemcitabine 5Capecitabine 5Bevacizumab 5Radiotherapy 4Fluorouracil 4Doxorubicin 4Sunitinib 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3seocalcitol 2regorafenib 2phosphomannopentaose sulfate 2atezolizumab 2Thiotepa 2Radiofrequency Ablation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Dexamethasone 2Cisplatin 2Chemoembolization, Therapeutic 2Carboplatin 2Busulfan 2Brachytherapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Liver Neoplasms × Vancomycin × Clear all
NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
22 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡